Seres Therapeutics MCRB
NASDAQ MCRB
$4.56 -0.01 (-0.22%)
At close: Aug 21, 2026 · 4:00 PM EDT

Seres Therapeutics (MCRB) Restructuring Costs (2019)

Seres Therapeutics (MCRB) posted Restructuring Costs of $1.5 million for Q1 2019.

Seres Therapeutics (MCRB) Restructuring Costs (2019) Analysis & Trends

Seres Therapeutics has reported Restructuring Costs for 1 years, with the latest figure at $1.5 million in Q1 2019.

  • Quarterly Restructuring Costs changed N/A year-over-year to $1.5 million in Q1 2019, while the trailing twelve-month figure through Dec 2019 was $1.5 million (changed N/A YoY) and the FY2019 annual result came in at $1.5 million, changed N/A from the prior year.
  • Restructuring Costs held at $1.5 million in Q1 2019 per MCRB's latest filing.
  • Over five years, Restructuring Costs peaked at $1.5 million in Q1 2019 and troughed at $1.5 million in Q1 2019.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn -
10 Seres Therapeutics 43.87 Mn 43.87 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2019 1.49 Mn